Mirvetuximab soravtansine

PubChem compound: 131704323

Therapeutic indications

Mirvetuximab soravtansine is indicated for:

FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer

Population group: only adults (18 years old or older)

Mirvetuximab soravtansine as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Mirvetuximab soravtansine is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: ELAHERE Concentrate for solution for infusion
Structured Product Labeling (SPL/PLR) 2023: ELAHERE Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈